title: Colonic perforation after rituximab treatment for posttransplant lymphoproliferative disorder.
authors.affiliation: Division of Pediatric Gastroenterology and Nutrition, A.I. duPont Hospital for Children, Wilmington, DE 19803, USA.
authors.forename: Erika
authors.initials: E
authors.lastname: Kutsch
authors.forename: Portia
authors.initials: P
authors.lastname: Kreiger
authors.forename: Deborah
authors.initials: D
authors.lastname: Consolini
authors.forename: Katryn N
authors.initials: KN
authors.lastname: Furuya
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002675:Child, Preschool; D012809:Colon, Sigmoid / Q000187:drug effects / Q000276:immunology / Q000473:pathology / Q000601:surgery; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D006097:Granulation Tissue / Q000187:drug effects / Q000473:pathology; D016027:Heart Transplantation / Q000009:adverse effects; D006801:Humans; D018636:Hypoplastic Left Heart Syndrome / Q000601:surgery; D016867:Immunocompromised Host / Q000187:drug effects; D007416:Intestinal Perforation / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D011183:Postoperative Complications / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D000069283:Rituximab; D012810:Sigmoid Diseases / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D015275:Tumor Lysis Syndrome / Q000209:etiology / Q000503:physiopathology*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab